Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/001—Preparation for luminescence or biological staining
  • A61K49/0013—Luminescence
  • A61K49/0017—Fluorescence in vivo
  • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
  • A61K49/0056—Peptides, proteins, polyamino acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
  • A61K38/46—Hydrolases (3)
  • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
  • A61K38/482—Serine endopeptidases (3.4.21)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K49/00—Preparations for testing in vivo
  • A61K49/001—Preparation for luminescence or biological staining
  • A61K49/0013—Luminescence
  • A61K49/0017—Fluorescence in vivo
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
  • A61P27/06—Antiglaucoma agents or miotics

Definitions

• the present invention is generally directed to the fields of ophthalmology and cell biology. Specifically, it relates to altering the physical and/or chemical properties of an ocular tissue. More specifically, it describes a means to detect and/or reduce the thickening and/or change the permeability of Bruch' s membrane associated with eye disorders, such as macular degeneration. Even more specifically, it regards administration of an inactivated diffusion-enhancing molecule to Bruch' s membrane followed by activation of the diffusion- enliacing molecule through an energy source.
• AMD Age related macular degeneration
• Macular degeneration is categorized as either dry (atrophic) or wet (neovascular).
• the dry form is more common than the wet, with about 90% of AMD patients diagnosed with dry AMD.
• the wet form of the disease usually leads to more serious vision loss.
• RPE retinal pigment epithelial cells
• atrophic AMD The clinical hallmark of atrophic AMD is accumulation of macular drusen, yellowish deposits just deep to the retinal pigment epithelium ("RPE"). Histopathologic examination of eyes with atrophic AMD reveals deposition of lipid and proteinaceous material deep to the RPE in Bruch' s membrane. In aged eyes with AMD, Bruch' s membrane is often about 3 times thicker than normal.
• This thickening is thought to be comprised of lipid as well as modified and cross-linked protein, which impedes transport of nutrients across Bruch' s membrane from the choriocapillaris to the outer retina
• This thickened barrier comprised of lipid and cross-linked protein impedes transport of nutrients across Bruch' s membrane from the choriocapillaris to the outer retina.
• ARMD may be caused by chronic exposure of the retina to light.
• AMD is a challenging disease for both patient and doctor, because there are very few treatment options and, with the exception of anti-oxidants, no proven preventative therapy. While some individuals experience only minor inconvenience from macular degeneration, many others with more severe forms of macular degeneration are incapacitated. Current therapies, including laser photocoagulation, photodynamic therapy, and anti-angiogenic therapeutics have had mixed results, and, in certain instances, have caused deleterious side effects. A need therefore exists for a treatment that reduces or limits the effects of macular degeneration.
• the compound Shortly after administration, the compound is activated with a pre-calculated dose of light at a particular wavelength, resulting in conversion of normal oxygen to free radical singlet oxygen, which in turn causes closure of neovascular tissue.
• the therapy in specific embodiments, treats the blood vessel proliferation.
• choroidal neovascularization with photodynamic therapy, recurrent neovascularization occurs commonly within several months after treatment.
• U.S. Patent No. 5,756,541 is directed to methods to improve visual acuity including administering a photoactive compound in an amount sufficient to localize to a target ocular tissue and irradiating the target tissue with light from a laser, wherein the wavelength of radiation is absorbed by the photoactive compound and the radiation is conducted for a time and at an intensity sufficient to improve visual acuity.
• the photoactive compound is a green porphyrin.
• U.S. Patent No. 5,910,510 is directed to an identical method having a particular irradiation timing.
• U.S. Patent No. 5,798,349 regards methods to treat conditions of the eye characterized by unwanted neovascularure, such as AMD, by administering a liposomal formulation of a green porphyrin in an amount and time sufficient to localize in the neovascularure, followed by irradiation of the neovasculature with laser light, wherein the light absorbed by the green porphyrin occludes the neovasculature.
• the irradiance is in a range from about 300 mW/cm 2 to about 900 mW/cm 2 .
• U.S. Patent No. 6,128,525 is directed to method and apparatus controlling dosimetry of photodynamic therapy.
• U.S. Patent No. 5,935,942 regards methods of occluding vasculature in a mammalian eye including co-administering intravenously a fluorescent dye encapsulated with heat-sensitive liposomes and a tissue-reactive agent activated by irradiation.
• the liposomes are heated in the eye to release their contents, wherein the tissue-reactive agent remains inactive, followed by monitoring of fluorescent dye flow within the vasculature.
• the tissue-reactive agent is activated in the vasculature having subnormal blood flow, such that the activated agent chemically occludes the vasculature.
• 6,140,314 methods further comprise coadministration of a tissue-specific factor effective to impair growth or regeneration of a blood vessel.
• the related U.S. 6,248,727 regards related diagnostic reagents and kits.
• the present invention regards methods and compositions for altering physical and/or chemical properties of an ocular tissue, hi specific embodiments, it refers to enhancement of diffusion through or across a tissue, targeted destruction of cells, and/or targeted alteration of at least part of at least one ocular tissue in an individual. This may be accomplished, in particular embodiments, using a means to effect a controlled enhancement of diffusion and/or other controlled alteration, such as with light or ultrasound. Some aspects of the present invention are directed to treating eye disorders at early stages, and a skilled artisan will recognize the utility of this invention for such a purpose.
• Bruch' s membrane is the targeted tissue. With aging and especially in macular degeneration, Bruch' s membrane develops a lipid and cross-linked protein barrier. Impaired diffusion across Bruch' s membrane in patients with macular degeneration, promotes release of angiogenic factors by the nutritionally deprived retina. This, in turn, causes growth of neovascular tissue through Bruch' s membrane with subsequent bleeding, leakage of serous fluid, and severe visual loss. Some aspects of the present invention allow treatment/administration before or shortly after choroidal neovascularization develops.
• the tissue-altering molecule is administered in inactive form, such as by systemic injection or ingestion, or local (intraocular, periocular) injection, hi a specific embodiment, the molecule is lipophilic. It binds to multiple tissues in an inactive form before it is gradually eliminated. It is only activated by an energy source ⁇ e.g. light, ultrasound, or both) that is precisely applied to the eye to achieve preferential activation of the tissue-altering substance in Bruch' s membrane.
• an energy source e.g. light, ultrasound, or both
• the tissue-altering molecules alter the lipids and/or cross-linked protein in Bruch' s membrane, such as to improve transmembrane diffusion.
• the photochemical activation steps comprise 2-photon photo-chemistry.
• an eye disorder comprising the step of increasing diffusion across Bruch's membrane in said eye.
• the increased diffusion is a result of reducing the thickness, altering the composition, or both, of said membrane.
• a method for increasing diffusion across Bruch's membrane in at least one eye of an individual comprising the steps of administering to the Bruch's membrane an inactive form of a degradation molecule in an amount sufficient to form a Bruch's membrane/inactive degradation molecule complex; and exposing said complex to an activating source, wherein said activating source activates said inactive degradation molecule into an active form of said degradation molecule, said activation resulting in an increase in diffusion across said membrane.
• the increase in diffusion is a result of reducing the thickness or altering the composition of said membrane.
• the increase in diffusion is a result of alteration of a lipid, a cross-linked protein, or both in the membrane.
• the individual has an eye disorder, such as AMD, juvenile macular degeneration, Sorby's fundus dystrophy, or age-related decrease in visual function unrelated to macular degeneration, h a specific embodiment, the inactive degradation molecule binds directly to the membrane.
• the inactive degradation molecule is a protein, detergent, surfactant (useful for caged cyclodextrin).
• the protein is an enzyme.
• the inactive enzyme is further defined as being caged by the incorporation of at least one photo- removable protecting group on an amino acid sidechain of said enzyme.
• the protecting group is o-nitrobenzyl, desyl, phenacyl, trans-o-cinnamoyl, coumarinyl, quinoline-2-only, xanthenyl, thioxanthenyl, selenoxanthenyl and anthracenyl, stilbenyl, or a combination thereof
• the protecting group is o- nitrobenzyl, desyl, phenacyl, trans-o-cinnamoyl, coumarinyl, quinoline-2-only, xanthenyl, thioxanthenyl, selenoxanthenyl and anthracenyl, stilbenyl or derivatives thereof
• the amino acid is cysteine, aspartate, glutamate, histidine, lysine, asparagine, glutamine, arginine, serine, threonine, tyrosine, or a combination thereof
• the protein is further defined as being caged in an ultrasound contrast agent.
• the ultrasound contrast agent is a microbubble or a liposome.
• the protein further comprises a protein binding domain.
• the protein binding domain is a heterodimeric domain.
• the protein binding domain is a leucine zipper domain, a chitin-binding domain, or a Src homology 2 (SH2) domain.
• the inactive degradation molecule is administered to the individual in a pharmacologically acceptable composition.
• the inactive degradation molecule is administered in a pharmacologically acceptable composition systemically to the individual.
• the inactive degradation molecule is administered in a pharmacologically acceptable composition to the individual orally, by injection (such as periocular or intraocular), rectally, vaginally, or topically.
• the enzyme is a matrix metalloproteinase, a cholesterol esterase, a lipase, a cathepsin, a protease, or a combination thereof.
• tissue-altering agent refers to at least one molecule that changes the physical, chemical, or both properties of a tissue.
• the term refers to an agent that alters a tissue such that diffusion through or across is improved, at least partially.
• the term refers to an agent that is capable of at least (that at least in part is undesirable) partially degrading components of a tissue.
• the term refers to an agent that is capable of reducing lipids and/or cross-linked proteins in a tissue, such as Bruch's membrane.
• the term regards degrading one or more of its components.
• the tissue-altering molecule is a detergent that can extract lipidic and non-lipidic deposits from within a tissue such as Bruch's membrane.
• ultrasound contrast agent refers to microstructures that can carry exogenous contrast agents. These microstructures can be disrupted by focused application of ultrasound irradiation. Examples include microbubbles (tiny gas bubbles, in suspension, that can strongly scatter ultrasound) or liposomes.
• the present invention is directed to the treatment of an eye disorder, particularly by effecting alteration of ocular tissue related to the disorder.
• This alteration may be of any kind, so long as the tissue is altered, but in particular embodiments it refers to enhancement of diffusion of a tissue using methods and compositions described herein.
• the methods and compositions affect Bruch's membrane to improve an ocular disorder.
• the present invention is directed to the treatment of glaucoma with topical administration of at least one tissue-altering agent.
• Such treatment is useful for glaucoma, such as for the particular embodiment of alleviating a clogged trabecular meshwork in the pathogenesis of glaucoma.
• the present invention regards treatment for macular degeneration, either dry or wet.
• wet AMD may be treated with the methods of the present invention, given that after treatment of wet macular degeneration by currently known methods, the condition commonly recurs (recurrent choroidal neovascularization).
• the therapy described herein prevents such recurrences and may limit the extent (growth) of existing choroidal neovascularization, thus maintaining better vision.
• the treatment by increasing nutritional delivery to the retina, the treatment causes regression of existing choroidal neovascularization.
• the present invention aims to treat eye disorders, such as macular degeneration, by focusing on the thickened Bruch's membrane associated with many eye disorders.
• This thickening is the result of abnormal deposition of lipid and cross-linked protein and precedes neovascularization through Bruch's membrane, followed by subsequent bleeding, leakage of serous fluid, and severe visual loss.
• an improvement in diffusion across Bruch's membrane is achieved, thereby reducing the lipid and cross-linked protein barrier that accumulates in individuals with eye disorders, to prevent development of visual loss.
• the chemical composition of the membrane is altered. For example, a detergent washes away lipids in the membrane. An enzyme degrades proteins within the membrane.
• the methods of the present invention result in an increase in hydraulic conductivity across Bruch's membrane and/or an increase in macromolecular and/or oxygen permeability of Bruch's membrane.
• an individual with signs or symptoms of an aging Bruch's membrane is administered, such as systemically or locally, an inactive tissue-altering molecule.
• the inactive molecules are visualizable prior to activation, such as by being fluorescent. Following sufficient time for adequate distrubution of the inactive molecules, the molecules accumulate within multiple tissues, including Bruch's membrane. Once sufficient amounts are reached at Bruch's membrane, the visualizability of the molecules is used to precisely target Bruch's membrane with an energy source, such as light or ultrasound, that activates the tissue-altering molecules selectively.
• the present invention is useful for visualization of Bruch's membrane, such as for diagnostic techniques. That is, an inactive fluorescent compound is administered to an individual and associates with Bruch's membrane, such as by binding a lipid in Bruch's membrane. Energy, such as in the form of light, or more specifically 2 photon irradiation, is focused on the complex of inactive photoactive compound/Bruch's membrane, and the inactive photoactive compound is then activated. Energy emitted from the photoactive compound, such as light, allows visualization of Bruch's membrane. In specific embodiments, the amount of light emitted is proportional to the amount of lipid in Bruch's membrane.
• the present invention utilizes a tissue-altering molecule for delivery to an ocular tissue, in specific embodiments for treatment in the eye.
• the tissue-altering molecule may be diffusion-enhancing, degradative, or both, and it preferably alters the physical, chemical, or both properties of the tissue.
• a diffusion-enhancing molecule acts to increase diffusion across Bruch's membrane by either a) reducing the thickness of the membrane itself; and/or b) reducing the amount of deposits within Bruch's membrane, and/or by changing the chemical nature of Bruch's membrane.
• the tissue-altering molecule is caged, hi other specific embodiments, the tissue-altering molecule is a degradative enzyme, such as cholesterol esterases, lipases, matrix metalloproteinases, or any enzyme, or protein in particular, such as that can increase diffusion across Bruch's membrane, preferably by degrading one or more of its components, hi other specific embodiments, the tissue-altering molecule is a detergent that can extract lipidic and non-lipidic deposits from within Bruch's membrane, which will increase diffusion across Bruch's membrane.
• a degradative enzyme such as cholesterol esterases, lipases, matrix metalloproteinases, or any enzyme, or protein in particular, such as that can increase diffusion across Bruch's membrane, preferably by degrading one or more of its components
• the tissue-altering molecule is a detergent that can extract lipidic and non-lipidic deposits from within Bruch's membrane, which will increase diffusion across Bruch's membrane.
• the tissue-altering molecule is formulated so as to provide an effective concentration in the desired tissue. Although in some embodiments the tissue-altering molecule accumulates in non-affected tissue, this is not problematic for the individual, since precise targeting of the activating energy source to Bruch's membrane renders selective activation within the membrane. Other regions where the caged tissue-altering molecules accumulate are not treated with the activating energy; therefore, the caged tissue-altering molecules remain inactive and are eliminated via the kidneys and/or liver. In a specific embodiment, the caged molecule is not harmful or toxic in any manner and is nevertheless excreted from the body, preferably less than about 48 hours after administration, and more preferably less than about 24 hours after administration.
• the tissue-altering molecule is coupled to a specific binding ligand that may bind to a specific target molecule within Bruch's membrane.
• the target molecule may be endogenous to Bruch's membrane, or may be selectively delivered to Bruch's membrane by crosslinking the target molecule using 2- ⁇ hoton irradiation, hi these embodiments, the tissue-altering molecule will be delivered in higher concentrations to the target tissue, hi a specific embodiment, various protein-binding domains such as leucine zipper domains are associated with the tissue-altering molecule.
• the tissue-altering molecule is formulated so as to provide an effective concentration in the desired tissue. Although in some embodiments the tissue-altering molecule accumulates in non-affected tissue, this is not problematic for the individual, since precise targeting of the activation energy source to Bruch's membrane renders selective activation within this tissue. Other regions where the caged tissue-altering molecules accumulate are not treated with the activating energy; therefore, the caged tissue-altering molecules remain inactive and are eliminated via the kidneys and/or liver, hi some embodiments, the tissue-altering molecule is coupled to a specific binding ligand that may bind to a specific surface component of the target Bruch's membrane or, if desired, by formulation with a carrier that delivers higher concentrations to the target tissue. In a specific embodiment, various protein binding domains such as leucine zipper domains are associated with the tissue-altering molecule.
• the nature of the formulation will depend in part on the mode of administration and on the nature of the selected degradation molecule. Any pharmaceutically acceptable excipient, or combination thereof, appropriate to the particular tissue-altering compound may be used.
• the compound may be administered as an aqueous composition, as a topical composition, as a transmucosal or transdermal composition, in an oral formulation or intravenous formulation, in a local injection (such as periocular or intraocular) or a combination thereof.
• the formulation may also include liposomes.
• tissue-altering molecule compound can be administered in any of a wide variety of ways, for example, orally, parenterally, or rectally, or the compound may be placed directly in the eye, such as topically or by periocular injection.
• Parenteral administration such as intravenous, intramuscular, or subcutaneous, is useful.
• Intravenous, periocular, and intraocular injection are particular embodiments for delivery of the present invention or components thereof.
• the dose of tissue-altering molecule can vary widely depending on the mode of administration; the formulation in which it is carried, such as in the form of liposomes; or whether it is coupled to a target-specific ligand, such as an antibody or an immunologically active fragment.
• a target-specific ligand such as an antibody or an immunologically active fragment.
• the various parameters used for effective, selective photo-activation of the tissue-altering molecules in the invention are interrelated. Therefore, the dose should also be adjusted with respect to other parameters, for example, fluence, irradiance, duration of treatment, and time interval between administration of the dose and the therapeutic irradiation. All of these parameters should be adjusted to produce enhancement of visual function without significant damage to the ocular tissue, and a skilled artisan is well aware how to do so.
• compositions and methods related to two-photon absorption are well known in the art, although exemplary methods are described in U.S. Patent No. 6,267,913, U.S. Patent No. 6,472,541, and WO 00/31588, which are all incorporated by reference herein in their entirety.
• Proteins may be caged using a number of strategies. Caging may be accomplished by treating the native, uncaged molecule with a reactive precursor to a caging group. For example, the sidechain of the amino acid cysteine may be caged with the photo- removable o-nitrobenzyl group by treating a cysteine-containing protein with o- nitrobenzylbromide.
• Alternative strategies for caging proteins include chemical synthesis of the protein using solid-phase peptide synthesis starting with the appropriate caged amino acids, by direct translational incorporation into proteins using methods based on nonsense suppression, or by supplementing auxotrophic strains of bacteria with the caged amino acids.
• a tissue-altering molecule is caged to render it inactive, prior to localization to Bruch's membrane and activation upon exposure to an energy source.
• the tissue-altering molecule is a protein having amino acid side chains.
• a protecting group such as a photo-removable protecting groups, include cysteine, aspartate, glutamate, histidine, lysine, asparagine, glutamine, arginine, serine, threonine, or tyrosine.
• photo-removable protecting groups includes o-nitrobenzyl, desyl, phenacyl, tr ⁇ «s-o-cinnamoyl, coumarinyl, quinoline-2-only, xanthenyl, thioxanthenyl, selenoxanthenyl and anthracenyl, stilbenyl, and/or derivatives thereof. These protecting groups are added to the side chains as described elsewhere herein.
• the retina is a multilayered structure that lines the inside of the globe. It is made up of specialized cells that convert the light to electrical impulses that travel to the brain and produce sight.
• atrophic AMD The primary characteristic of atrophic AMD is accumulation of macular drusen, a localized thickening of Bruch's membrane. Diffuse thickening of Bruch's membrane (basal linear deposit) is the best histopathologic predictor of choroidal neovascularization.
• the drusen are primarily comprised of vesicular material (lipids) and cross-linked protein [0067]
• the presence of drusen is a common characteristic of macular degeneration.
• an individual having at least one eye with drusen or a thickened Bruch's membrane is treated with methods described herein.
• Caged tissue-altering enzymes are constructed by masking various amino acid sidechains within the protein using photo-removable protecting groups.
• groups are the o-nitrobenzyl, desyl, phenacyl, trar ⁇ -o-cinnamoyl, coumarinyl, quinoline-2-only, xanthenyl, thioxanthenyl, selenoxanthenyl and anthracenyl, stilbenyl and derivatives thereof.
• These groups are introduced into the proteins by total chemical synthesis (including native chemical ligation), nonsense suppression methods, or post-translational modification.
• mild detergent molecules ⁇ e.g. surfactant
• mild detergent molecules are "caged” using groups such as the o-nitrobenzyl, desyl, phenacyl, tr ⁇ ras- ⁇ -cinnamoyl, coumarinyl, quinoline-2- only, xanthenyl, thioxanthenyl, selenoxanthenyl and anthracenyl, and/or stilbenyl moieties and their derivatives thereof and likewise activated by irradiation (for example, by 2-photon irradiation) to effect selective biochemical modification of Bruch's membrane. Similar to enzyme treatment, these activated detergent molecules alter the diffusion barrier of aged Bruch's membrane to lessen the likelihood of visual loss and/or improve visual function.
• groups such as the o-nitrobenzyl, desyl, phenacyl, tr ⁇ ras- ⁇ -cinnamoyl, coumarinyl, quinoline-2- only, xantheny
• an acidic (basic) leucine zipper domain may be selectively delivered to Bruch's membrane via photo-crosslinking initiated by 2-photon irradiation.
• the enzyme is fused to a basic (acidic) leucine zipper domain and is administered, for example, systemically (such as orally or intravenously), or by injection (such as intraocular and/or periocular injection) and distributed to extracellular tissues, including Bruch's membrane. Formation of hetero-dimers within Bruch's membrane increases the local concentration of degradative enzymes and subsequently enhances trans-membrane diffusion properties. Because the concentration of these degradative enzymes will remain low in other tissues, there are no undesired collateral tissue alterations.
• the caged, inactivated molecule is fluorescent.
• the fluorescent, caged degradative complex is viewed in macular Bruch's membrane by 2 photon irradiation. After focusing on the fluorescent label in macular Bruch's membrane, a higher dose of 2 photon irradiation is applied to uncage the enzyme and initiate partial degradation of Bruch's membrane. Systemically distributed non- irradiated caged enzyme is excreted in its inactive form. Two photon irradiation viewing of labeled Bruch's membrane and photoactivation of the degradative substance are both performed at levels non-toxic to ocular structures.
• Optical coherence tomography with visible or infrared light is used to detect alterations in the physical or chemical nature of Bruch's membrane in the eye.
• OCT can be used to see not only the structure in the eye but also the mobility of the structures by Doppler OCT and the chemical nature by combining the OCT with an exogenous dye.
• the OCT and/or its variants are used to determine the nature of the Bruch's membrane with altered properties to permit guided treatment. Treatment could be the photo- uncaging or photo-activation or photo-ablation of intrinsic or extrinsic substances in or near Bruch's membrane.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biomedical Technology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Ophthalmology & Optometry (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
• Investigating Or Analysing Materials By Optical Means (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (2)

Family

ID=30115595

Family Applications (1)

Country Status (6)

Cited By (3)

Families Citing this family (25)

Citations (4)

Family Cites Families (33)

• 2003
  • 2003-07-01 EP EP03763073A patent/EP1539222A1/en not_active Withdrawn
  • 2003-07-01 CN CNA038208113A patent/CN1678342A/zh active Pending
  • 2003-07-01 WO PCT/US2003/020672 patent/WO2004004757A1/en not_active Ceased
  • 2003-07-01 US US10/611,013 patent/US7381404B2/en not_active Expired - Fee Related
  • 2003-07-01 CA CA002491128A patent/CA2491128A1/en not_active Abandoned
  • 2003-07-01 JP JP2004519718A patent/JP2005532393A/ja active Pending
• 2008
  • 2008-05-23 US US12/126,100 patent/US8298521B2/en not_active Expired - Fee Related

Patent Citations (4)

Also Published As

Similar Documents

Legal Events